COMMUNIQUÉS West-GlobeNewswire

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
25/01/2024
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis [...]
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
25/01/2024
CUPERTINO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
25/01/2024
CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
25/01/2024
SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ocular [...]
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
25/01/2024
Company eliminates three executive officer roles and appoints new Executive Leadership team SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated [...]
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
25/01/2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“ [...]
Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
25/01/2024
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Cancers from a team of cancer researchers primarily at the NCI-Designated Cancer Center, [...]
SS Innovations Partners with India’s Leading Medical Equipment Supplier, Medikabazaar
25/01/2024
Collaboration to facilitate sales of the SSi Mantra Surgical Robotic System to hospitals and medical facilities across India FORT LAUDERDALE, Fla., Jan. 25, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. ( [...]
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
25/01/2024
New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac Function and Stabilization of Fibrosis SOUTH SAN [...]
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
25/01/2024
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for eligible patients. ANN [...]
ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review
25/01/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the European regulatory filing for ACARIZAX ® (house dust mite sublingual immunotherapy tablet) in young children has been accepted for review by the relevant [...]
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
25/01/2024
BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy ( [...]
Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.
25/01/2024
Webinar to be hosted on January 31, 2024 at 1:00 pm. ET CHATHAM, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with [...]
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
25/01/2024
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The [...]
Cronos’ Spinach® Brand Ends 2023 as the Number One Flower Brand in Canada1
25/01/2024
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that its brand, Spinach ® , closed 2023 as [...]
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
25/01/2024
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated patients is anticipated in 2Q 2024 Pamrevlumab is the first experimental arm to meet its [...]
Embrace the Taste of Paradise with Breckenridge Brewery’s Refreshing New ‘Juicy Oasis Fruited Hazy IPA’
25/01/2024
LITTLETON, Colo., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery (“Breck Brewery” or “Breck Brew”) a subsidiary of Tilray Brands, Inc . (“Tilray” or the “Company”) (NASDAQ: TLRY and TSX: TLRY), is thrilled to [...]
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
25/01/2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of [...]
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
25/01/2024
Interim Data Analysis Anticipated in Mid-2024 Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive [...]

Pages